Drug intelligence / Profile preview

GPCR 3 program

Development stage: Preclinical
Lead developer: Superluminal Medicines
Modality: Small Molecules

Overview

GPCR 3 program is a preclinical drug candidate being developed by Superluminal Medicines. It consists of small-molecule positive and/or negative allosteric modulators (PAMs/NAMs) targeting an undisclosed G protein-coupled receptor (GPCR). The program is currently in the Hit-to-Lead stage of development. Superluminal Medicines utilizes a proprietary discovery platform that integrates structural biology, chemistry, and machine learning to design highly selective GPCR-targeted treatments. While the specific target and indications for this program are currently undisclosed, the company's broader pipeline is focused on addressing endocrine and cardiometabolic diseases.

Other names: Superluminal Medicines GPCR 3 program

Beyond the preview

Go deeper on GPCR 3 program.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GPCR 3 program.

Explore the full profile